Fisher & Paykel Healthcare Corporation Limited · NZX:FPH
Fisher & Paykel Healthcare — Shareholder Meeting (August 2012)
25 slides from Fisher & Paykel Healthcare's shareholder meeting presentation, Aug 22, 2012
Slide 1: Annual Shareholders' Meeting 2012
Annual Shareholders’ Meeting 2012 22 August 2012
Slide 2: Tony Carter - Chairman
Tony Carter - Chairman Fisher & Paykel 2 HEALTHCARE
Slide 3: Directors
Directors • Tony Carter (Chairman) • Michael Daniell (Managing Director & CEO) • Nigel Evans • Roger France • Lindsay Gillanders • Arthur Morris • Gary Paykel 3
Slide 4: Annual Shareholders' Meeting 2012
Annual Shareholders’ Meeting 2012 22 August 2012 4
Slide 5: 10 Years On
10 Years On 2 500 1,000 $911.3 400 800 300 600 200 400 100 200 $114.6 O 0 2003 2012 2003 2012 US$ REVENUE (US$000) CUMULATIVE GROSS DIVIDEND (NZ$000) Fisher & Paykel 5 HEALTHCARE
Slide 6: Annual Shareholders' Meeting 2012
Annual Shareholders’ Meeting 2012 22 August 2012 6
Slide 7: Our International Presence
Our International Presence 7
Slide 8: Annual Shareholders' Meeting 2012
Annual Shareholders’ Meeting 2012 22 August 2012 8
Slide 9: Michael Daniell – MD/CEO
Michael Daniell — MD/CEO Fisher & Paykel 9 HEALTHCARE
Slide 10: Consistent Growth Strategy
Consistent Growth Strategy US $ Millions Operating Revenue 417.1 371.0 • Innovative devices which 341.5 improve care and outcomes 299.3 271.5 229.1 • Increase value per patient • New clinical applications • International expansion 07 08 09 10 11 12 10
Slide 11: Financial Summary
Financial Summary 12 Months Ended 12 Months Ended % 31 March 2011 31 March 2012 Change Operating Revenue (NZ$m) 506.1m 516.7m +2% Operating Revenue (Constant Currency) 475.0m 514.1m +8% Operating Margin 19% 18% Net Profit (NZ$m) 63.9m 64.1m - Net Profit (Constant Currency) 39.8m 48.9m +23% 11
Slide 12: Product Groups
Product Groups • Consumable and accessory products 75% of core product revenue Operating revenue 12 months to 31 March 2012 12
Slide 13: Global Sales
Global Sales • Sales in more than 120 countries • 99% outside New Zealand Operating revenue 12 months to 31 March 2012 13
Slide 14: Respiratory & Acute Care
Respiratory & Acute Care Fisher & Paykel 14 HEALTHCARE
Slide 15: New Applications Growing
New Applications Growing —_-—«—,_ OPTIFLOw, CANNULA. ™ FreeMotion oPTIFLOw NASAL LOW FLOW IGH FLOW — OXYGEN pAVBIHL dg, Optiflow” junior Bubble CPAP ky oo “'Sive venti-A™ Fisher & Paykel HEALTHCARE 15
Slide 16: Fisher & Paykel
Fisher & Paykel 16 HEALTHCARE
Slide 17: AIRVO
AIRVO" 2 + ¥ | * < | ° | | Fisher & Paykel 17 HEALTHCARE
Slide 18: Obstructive Sleep Apnea
Obstructive Sleep Apnea Lady Zest"Q Fisher & Paykel 18 HEALTHCARE
Slide 19: Auto Premo Novo
ICON” Auto Premo Novo ThermoSmart™ ThermoSmart™ ThermoSmart™ ~& SensAwake" ~&> SensAwake” Fisher & Paykel 19 HEALTHCARE
Slide 20: Pilairo
Pilairo” AAR ER Fisher & Paykel 20 HEALTHCARE
Slide 21: Eson
Eson” Fisher & Paykel 21 HEALTHCARE
Slide 22: Earnings Growth Drivers
Earnings Growth Drivers • Accelerating revenue growth • New products, increased margins • Capacity increase in Mexico • Lean manufacturing, automation, supply chain optimisation • Reduced expense growth rate • Currency diversification • Foreign exchange hedging Mexico facility 22
Slide 23: Fisher & Paykel
Fisher & Paykel 23 HEALTHCARE
Slide 24: Outlook
Outlook First Half • Operating revenue – NZ$265 million approx. • Profit after tax – NZ$31 million approx. Full Year • Expect over NZD:USD exchange rate range of 0.78 - 0.82 – Operating revenue NZ$540M - NZ$550M – Net profit after tax NZ$65M - NZ$69M 24
Slide 25: Annual Shareholders' Meeting 2012
Annual Shareholders’ Meeting 2012 22 August 2012 25
Fisher & Paykel Healthcare — Shareholder Meeting (August 2012) on 6ix